All In Biotech

Drug Trial Radar · NCT07414290

A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R08b in Parkinson's Disease Patients With GBA1 Mutations

A Phase I/II Clinical Study to Evaluate the Tolerability, Safety, and Efficacy of VGN-R08b Intra-cerebroventricular Injection in Parkinson's Disease Patients With GBA1 Mutations

Last checked: Nov 20, 2026Latest source record: May 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

17

Planned (sponsor's estimate)

Start

May 25, 2026

Primary completion

Sep 1, 2027

Study completion Sep 1, 2031

Sponsor

Sponsor type
Industry
First posted
Feb 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 30 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase I/II Clinical Study to Evaluate the Tolerability, Safety, and Efficacy of VGN-R08b Intra-cerebroventricular injection in Parkinson's Disease Patients with GBA1 Mutations

Conditions

  • Parkinson Disease (PD)

Interventions

  • VGN-R08b 4.2×10^13 vgDrug

    Intracerebroventricular injection

  • VGN-R08b 8.4×10^13 vgDrug

    Intracerebroventricular injection

  • VGN-R08b 1.68×10^14 vgDrug

    Intracerebroventricular injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Adverse Events (AEs), Serious Adverse Events (SAEs)Vital signsTime frame: up to Week 52

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Xiangya Hospital, Central South University

    Changsha, Hunan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.